This website is best viewed in IE9 and above. Please upgrade your browser.

X

Study Connect Homepage » Protocol

Find out when studies you're interested in open or close, and when new information is posted

Study ID ( Protocol Number ) CV205-005

If you would like to be contacted about this study by a doctor's office or clinic, please select a location and register below (if available).

GO

No study locations were found within your desired distance. Please consider changing your distance limit above or subscribe to be alerted if new study location becomes available based on your original search criteria.

Alert me!
COMPLETE LIST OF US SITES

The above listing doesn't contain all study locations. For more information on participating countries & other details,please visit clinicaltrials.gov.

Study Name

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Share this Study

Study Overview

The purpose of this study is to evaluate the effect of BMS-919373 on atrial fibrillation (AF) through its effect on AF burden (AFB), or the percent of time in AF, in subjects with paroxysmal AF (pAF) when administered orally at a range of doses (2 mg once daily (QD), 5 mg QD, 12 mg QD following a 1-week period of loading doses of 3 mg QD, 8 mg QD and 20 mg QD, respectively) for a total of 4 weeks. It is hypothesized that treatment with BMS-919373 will reduce AF burden as compared to baseline relative to placebo.

Full Study info
at www.clinicaltrials.gov
Find a Study

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.

Have questions? Call 855-907-3286

The individuals who appear throughout this site are for illustrative purposes only. Except where noted, all persons
depicted are models and not real patients.

© 2016 Bristol-Myers Squibb Your use of the information on this site is subject to the terms of our
Legal Notice and Privacy Policy.